Investigation of the effects of polymymyxins on sub-proteome and lipidome of K. pneumonia

The worldwide use of antibiotics results in the development of bacterial resistance, which poses a threat to the healthcare. With the dearth in the discovery and development of new antibiotics and rapid emergence of multidrug resistant (MDR) Gram-negative bacteria, the optimisation of clinically available antibiotics is highly warranted. For this critical situation, polymyxins, an “old-antibiotic” have been re-birthed as the last therapeutic option for the treatment of the serious bacterial infections. The administration of polymyxins as a single therapy is unlikely to achieve optimal and safe plasma concentration particularly with highly resistant pathogens. To overcome these limitations with polymyxins therapy, a combination with other antibiotics is an option. Better understanding the mode of actions of polymyxin combination therapy is crucially important to achieve maximum benefit.